Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...

Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, February 05 based on AAII’s Stock Grades.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...